Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas

Blood

Volumn 119, Issue 21, 2012, Pages 4838-4844

  Kuo, Sung Hsin ^a   Yeh, Kun Huei ^a   Wu, Ming Shiang ^a   Lin, Chung Wu ^a   Hsu, Ping Ning ^a   Wang, Hsiu Po ^a   Chen, Li Tzong ^b,c,d   Cheng, Ann Lii ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTINEOPLASTIC AGENT; BISMUTH CITRATE; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CANCER GRADING; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTROSCOPY; HELICOBACTER INFECTION; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; STOMACH LYMPHOMA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84861515828     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-404194     Document Type: Article

References (40)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
2. Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood. 2008; 112(12):4384-4399.
3. Isaacson PG, Du MQ. Gastrointestinal lymphoma: where morphology meets molecular biology. J Pathol. 2005;205(2):255-274. (Pubitemid 40227996)
4. Hussell T, Isaacson PG, Crabtree JE, Spencer J. The response of cells from low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet. 1993; 342(8871):571-574. (Pubitemid 23259232)
5. Neubauer A, Thiede C, Morgner A, et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst. 1997;89(18):1350-1355. (Pubitemid 27418025)
6. Zucca E, Dreyling M; ESMO Guidelines Working Group. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21(suppl 5):175-176.
7. Chen LT, Lin JT, Shyu RY, et al. Prospective study of Helicobacter pylori eradication therapy in stage I(E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. J Clin Oncol. 2001;19(22):4245-4251.
8. Chen LT, Lin JT, Tai JJ, et al. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst. 2005;97(18):1345-1353. (Pubitemid 41487802)
9. Nakamura S, Matsumoto T, Suekane H, et al. Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori. Gut. 2001;48(4):454-460. (Pubitemid 32234787)
10. Morgner A, Miehlke S, Fischbach W, et al. Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol. 2001;19(7):2041-2048. (Pubitemid 32702549)
11. Isaacson PG, Spencer J, Wright DH. Classifying primary gut lymphomas. Lancet. 1988;2(8620): 1148-1149.
12. Kuo SH, Chen LT, Wu MS, et al. Differential response to H. pylori eradication therapy of co-existing diffuse large B-cell lymphoma and MALT lymphoma of stomach-significance of tumour cell clonality and BCL10 expression. J Pathol. 2007; 211(3):296-304.
13. Salam I, Durai D, Murphy JK, Sundaram B. Regression of primary high-grade gastric B-cell lymphoma following Helicobacter pylori eradication. Eur J Gastroenterol Hepatol. 2001;13(11):1375-1378. (Pubitemid 33111986)
14. Sugimoto M, Kajimura M, Sato Y, Hanai H, Kaneko E, Kobayashi H. Regression of primary gastric diffuse large B-cell lymphoma after eradication of Helicobacter pylori. Gastrointest Endosc. 2001;54(5):643-645. (Pubitemid 33666040)
15. Alsolaiman MM, Bakis G, Nazeer T, MacDermott RP, Balint JA. Five years of complete remission of gastric diffuse large B cell lymphoma after eradication of Helicobacter pylori infection. Gut. 2003; 52(4):507-509. (Pubitemid 36363401)
16. Boot H, de Jong D. Diagnosis, treatment decisions, and follow-up in primary gastric lymphoma. Gut. 2002;51(5):621-622. (Pubitemid 35216843)
17. Fischbach W. Gastric mucosa-associated lymphoid tissue lymphoma: a challenge for endoscopy. Gastrointest Endosc. 2008;68(4):632-634.
18. Boot H. Diagnosis and staging in gastrointestinal lymphoma. Best Pract Res Clin Gastroenterol. 2010;24(1):3-12.
19. Ruskoné-Fourmestraux A, Fischbach W, Aleman BM, et al. EGILS group. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut. 2011;60(6):747-758.
20. Chan JK, Ng CS, Isaacson PG. Relationship between high-grade lymphoma and low-grade B-cell mucosa-associated lymphoid tissue lymphoma (MALToma) of the stomach. Am J Pathol. 1990;136(5):1153-1164. (Pubitemid 20188502)
21. de Jong D, Boot H, van Heerde P, Hart GA, Taal BG. Histological grading in gastric lymphoma: pretreatment criteria and clinical relevance. Gastroenterology. 1997;112(5):1466-1474. (Pubitemid 27181369)
22. Kuo SH, Yeh PY, Chen LT, et al. Overexpression of B cell-activating factor of TNF family (BAFF) is associated with Helicobacter pylori-independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma. Blood. 2008;112(7):2927-2934.
23. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56(6):772-781. (Pubitemid 46854190)
24. Chey WD, Wong BC. Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007; 102(8):1808-1825. (Pubitemid 47206706)
25. Du MQ, Isaccson PG. Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol. 2002; 3(2):97-104. (Pubitemid 34162980)
26. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993;342(8871):575-577. (Pubitemid 23259233)
27. Cavanna L, Pagani R, Seghini P, Zangrandi A, Paties C. High grade B-cell gastric lymphoma with complete pathologic remission after eradication of Helicobacter pylori infection: report of a case and review of the literature. World J Surg Oncol. 2008;6:35.
28. Wöhrer S, Puspok A, Drach J, Hejna M, Chott A, Raderer M. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. Ann Oncol. 2004;15(7):1086-1090. (Pubitemid 39089786)
29. Fischbach W. Long-term follow-up of gastric lymphoma after stomach conserving treatment. Best Pract Res Clin Gastroenterol. 2010;24(1):71-77.
30. Leopardo D, Di Lorenzo G, De Renzo A, et al. Efficacy of rituximab in gastric diffuse large B cell lymphoma patients. World J Gastroenterol. 2010; 16(20):2526-2530.
31. Raderer M, Valencak J, Osterreicher C, et al. Chemotherapy for the treatment of patients with primary high grade gastric B-cell lymphoma of modified Ann Arbor stages IE and IIE. Cancer. 2000;88(9):1979-1985. (Pubitemid 30233197)
32. Wöhrer S, Troch M, Raderer M. Treatment of localized primary gastric lymphoma. J Clin Oncol. 2006;24(17):2682. (Pubitemid 46622092)
33. Steinbach G, Ford R, Glober G, et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue: an uncontrolled study. Ann Intern Med. 1999;131(2):88-95. (Pubitemid 29340559)
34. Ruskone-Fourmestaux A, Lavergne A, Aegerter PH, et al. Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut. 2001;48(3):297-303. (Pubitemid 32269554)
35. Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut. 2004;53(1):34-37. (Pubitemid 38083007)
36. Tari A, Asaoku H, Kashiwado K, et al. Predictive value of endoscopy and endoscopic ultrasonography for regression of gastric diffuse large B-cell lymphomas after Helicobacter pylori eradication. Dig Endosc. 2009;21(4):219-227.
37. Govi S, Patti C, Raderer M, et al. Final results of a multicenter phase II trial assessing the activity and efficacy of Helicobacter pylori-eradicating antibiotic therapy as exclusive treatment for patients with stage I-II1 diffuse large B-cell lymphoma of the stomach (the HGL-1 Trial) [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21): Abstract 958.
38. Barth TF, Dohner H, Werner CA, et al. Characteristic pattern of chromosomal gains and losses in primary large B-cell lymphomas of the gastrointestinal tract. Blood. 1998;91(11):4321-4330. (Pubitemid 28261997)
39. Barth TF, Bentz M, Leithauser F, et al. Molecularcytogenetic comparison of mucosa associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tract. Genes Chromosomes Cancer. 2001;31(4):316-325. (Pubitemid 32622708)
40. Barth TF, Barth CA, Kestler HA, et al. Transcriptional profiling suggests that secondary and primary large B-cell lymphomas of the gastrointestinal (GI) tract are blastic variants of GI marginal zone lymphoma. J Pathol. 2007;211(3):305-313. (Pubitemid 46172706)